Emmanuelle Trombe represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerings, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities.
Emmanuelle Trombe is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is recommended for her expertise in the pharmaceutical, health care, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded.
Represented DBV Technologies on its US$281.5 million offering on NASDAQ
Represented DBV on its collaboration agreement with Nestlé Health Science for the development and commercialization of a novel diagnostic test for pediatric milk allergy
Represented Arterial Remodeling Technologies (ART), a French medtech developing an active bioabsorbable stent for the treatment of coronary disease, on its structured sale to the Japanese group Terumo Corporation
Chambers Europe 2014 – 2018, Band 1, Pharma/Life Sciences (France): Emmanuelle is recommended for her expertise in “commercial, corporate and regulatory matters in the industry of healthcare and medical devices.” She was described as: “very knowledgeable in pharma, bio-technology and licensing agreements. She is also very business-oriented.”
The Legal 500 EMEA 2017, Healthcare and Life Sciences-France
The Best Lawyers in France 2019, Biotechnology and Life Sciences Practice
Médecins sans Frontières, regularly provides contractual advice to this international humanitarian medical association
École Supérieure de Commerce de Paris (ESCP)
University of Paris II Panthéon-Assas, LLM (Maîtrise), Tax and Commercial Law
Complutense University of Madrid, Master AMSEC
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.